RecruitingEarly Phase 1NCT05745532
Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients
Sponsor
Shenzhen Hemogen
Enrollment
10 participants
Start Date
Dec 1, 2020
Study Type
INTERVENTIONAL
Conditions
Summary
This is an open label study to evaluate the safety and efficacy of β-globin Restored Autologous Hematopoietic Stem Cells in ß-Thalassemia Major Patients
Eligibility
Min Age: 8 YearsMax Age: 16 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a biological treatment called β-globin restored autologous hematopoietic stem cells for people with thalassemia. The study is currently recruiting participants at 1 location. People eligible for this study include aged 8 Years to 16 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALβ-globin restored autologous hematopoietic stem cells
β-globin-restored autologous hematopoietic stem cells modified with LentiHBBT87Q
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05745532
Related Trials
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
NCT0439862871 locations
CINC424A2X01B Rollover Protocol
NCT02386800101 locations
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
NCT06609226105 locations
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
NCT057364196 locations
A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East
NCT072159752 locations